Evidence map›Paper›PMID 38831285›Full record

ArticleBMC public health2024

Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population.

Alyona Mazhnaya, Brogan Geurts, Krestina Brigida, Shokhista Bakieva, Shakhlo Sadirova, Annika Witzigmann, Erkin Musabaev, Michael Brandl, Heide Weishaar, Sandra Dudareva and 1 more

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alyona MazhnayaCentre for International Health Protection, Robert Koch Institute, Berlin, Germany. hmazhnaya@gmail.com.
Brogan GeurtsCentre for International Health Protection, Robert Koch Institute, Berlin, Germany.
Krestina BrigidaResearch Institute of Virology, Tashkent, Uzbekistan.
Shokhista BakievaResearch Institute of Virology, Tashkent, Uzbekistan.
Shakhlo SadirovaResearch Institute of Virology, Tashkent, Uzbekistan.
Annika WitzigmannCentre for International Health Protection, Robert Koch Institute, Berlin, Germany.
Erkin MusabaevResearch Institute of Virology, Tashkent, Uzbekistan.
Michael BrandlDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Heide WeishaarCentre for International Health Protection, Robert Koch Institute, Berlin, Germany.
Sandra DudarevaDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Charbel El BcheraouiCentre for International Health Protection, Robert Koch Institute, Berlin, Germany.

Funding

German Federal Ministry of Health ZMI1-2521GHP906
6 · The paper itself

Abstract

introductionIn the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions.

methodsThis study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan.

resultsFollowing the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator.

conclusionsA multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs.

Indexed as

Health PersonnelQualitative ResearchAdultCross-Sectional StudiesFemaleFocus GroupsHealth Services AccessibilityHepatitis, Viral, HumanHumansInterviews as TopicMaleMass ScreeningMiddle AgedStakeholder ParticipationUzbekistanBarriers and facilitatorsBehavior changeCentral AsiaEliminationHepatitis testing

Identifiers

PMID38831285
PMCPMC11145832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.